Literature DB >> 30519774

HIV-associated cancers: the role of a unique multidisciplinary board to optimize patient's care behalf the CANCERVIH Group.

Aurelien Gobert1, Jean-Philippe Spano2,3, Jacques Cadranel4.   

Abstract

Since 1996, the life expectancy of people living with HIV (PLWHIV) has improved, while their risk of cancer is 2-3 times higher than in the general population. HIV-associated cancers remain a critical issue in this population and represent a particular care challenge due to the high risk of drug interactions and additive toxicity. The new standards of care with immunotherapy will also become a major issue for PLWHIV because of the potential impact on immunology and virology. Thus, the National Cancer Institute created the CANCERVIH national network in 2014 in France, enabling the establishment of a multidisciplinary national board of experts. This is an important first step that will help patients and health professionals provide optimal treatment to PLWHIV and prevent disparities. We hope that such a multidisciplinary council will make its voice heard in other countries and that this could be useful for patients with HIV-related cancers.

Entities:  

Keywords:  Cancer; HIV; Healthcare

Mesh:

Year:  2018        PMID: 30519774     DOI: 10.1007/s12032-018-1224-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  5 in total

Review 1.  HIV-Associated Cancers and Related Diseases.

Authors:  Robert Yarchoan; Thomas S Uldrick
Journal:  N Engl J Med       Date:  2018-03-15       Impact factor: 91.245

2.  PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?

Authors:  A Lavolé; A Guihot; M Veyri; O Lambotte; B Autran; N Cloarec; G Le Garff; T Flament; J Cadranel; J-P Spano
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

Review 3.  Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.

Authors:  J-P Spano; I Poizot-Martin; D Costagliola; F Boué; O Rosmorduc; A Lavolé; S Choquet; P-E Heudel; V Leblond; J Gabarre; M-A Valantin; C Solas; A Guihot; G Carcelain; B Autran; C Katlama; L Quéro
Journal:  Ann Oncol       Date:  2015-12-17       Impact factor: 32.976

4.  Disparities in cancer treatment among patients infected with the human immunodeficiency virus.

Authors:  Gita Suneja; Chun Chieh Lin; Edgar P Simard; Xuesong Han; Eric A Engels; Ahmedin Jemal
Journal:  Cancer       Date:  2016-05-17       Impact factor: 6.860

5.  Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America.

Authors:  Eric A Engels; Elizabeth L Yanik; Willian Wheeler; M John Gill; Meredith S Shiels; Robert Dubrow; Keri N Althoff; Michael J Silverberg; John T Brooks; Mari M Kitahata; James J Goedert; Surbhi Grover; Angel M Mayor; Richard D Moore; Lesley S Park; Anita Rachlis; Keith Sigel; Timothy R Sterling; Jennifer E Thorne; Ruth M Pfeiffer
Journal:  Clin Infect Dis       Date:  2017-08-15       Impact factor: 9.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.